Azithromycin vs erythromycin for the management of preterm premature rupture of membranes
American Journal of Obstetrics and Gynecology Mar 27, 2019
Navathe R, et al. - In this multicenter, retrospective cohort of women with singleton pregnancies with confirmed rupture of membranes between 230 to 336 weeks from January 2010 to June 2015, researchers examined patients treated with different dosing regimens of azithromycin vs erythromycin to assess if they differ in the latency from preterm premature rupture of membranes (PPROM) to delivery. Inclusion criteria were met by 453 patients. Findings revealed that no difference exists in latency to delivery, incidence of chorioamnionitis, or neonatal outcomes, with exception of respiratory distress syndrome being more common in the 5 day azithromycin group, when different dosing regimens of the azithromycin were compared with erythromycin. In the expectant management of PPROM,
if erythromycin is unavailable or contraindicated, consideration could be given to azithromycin as an alternative to erythromycin. An extended course of azithromycin beyond the single day dosing seemed to provide no additional benefit, however final recommendations on dosing strategies should rely on clinical trials.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
